We are live on ! Find out more
YARW

Yarrow Bioscience, Inc. Common Stock

52 hedge funds and large institutions have $110M invested in Yarrow Bioscience, Inc. Common Stock in 2019 Q2 according to their latest regulatory filings, with 6 funds opening new positions, 24 increasing their positions, 7 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

243% more repeat investments, than reductions

Existing positions increased: 24 | Existing positions reduced: 7

20% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 5

0% more ownership

Funds ownership: 0.02%0.02% (+0%)

2% less funds holding

Funds holding: 5352 (-1)

21% less capital invested

Capital invested by funds: $139M → $110M (-$29.4M)

50% less funds holding in top 10

Funds holding in top 10: 21 (-1)

Holders
52
Holders Change
-1
Holders Change %
-1.89%
% of All Funds
1.13%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.02%
New
6
Increased
24
Reduced
7
Closed
5
Calls
Puts
Net Calls
Net Calls Change

YARW Hedge Fund Activity: Q2 2019 in Review

52 of the 4,605 institutional investors tracked by Wall St. Rank reported a position in Yarrow Bioscience, Inc. Common Stock (YARW) for Q2 2019, worth a combined $110M — down 21% from $139M a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new YARW positions and 5 closed out — a net gain of 1 holder — while 24 added to existing stakes and 7 trimmed.

The largest buyer was Mangrove Partners, adding an estimated $2M. The largest seller was Great Point Partners, cutting an estimated $2.2M.

  • 52 institutional investors held Yarrow Bioscience, Inc. Common Stock (YARW) as of Q2 2019, down from 53 in Q1 2019.
  • Funds reported $110M of Yarrow Bioscience, Inc. Common Stock stock for Q2 2019, down 21% quarter-over-quarter.
  • 6 funds opened new Yarrow Bioscience, Inc. Common Stock positions in Q2 2019 and 5 closed out, a net change of +1 holder.
  • The largest Yarrow Bioscience, Inc. Common Stock buyer in Q2 2019 was Mangrove Partners, an estimated $2M added.
  • The largest Yarrow Bioscience, Inc. Common Stock seller in Q2 2019 was Great Point Partners, an estimated $2.2M sold.

Based on aggregated 13F filings for Q2 2019.